← Back to guidelines
Pathology7 papers

Basal cell carcinoma of chest wall

Last edited: 2 h ago

Overview

Basal cell carcinoma (BCC) of the chest wall is a type of non-melanoma skin cancer arising from basal cells of the epidermis. It typically presents as a slowly growing, locally invasive lesion with minimal potential for metastasis but significant risk of local tissue destruction if left untreated. Commonly affecting sun-exposed areas, chest wall BCC can occur in individuals of any age but is more prevalent in middle-aged to elderly populations, particularly those with fair skin and a history of chronic sun exposure. Early detection and appropriate management are crucial to prevent extensive tissue damage and functional impairment. This matters in day-to-day practice as timely intervention can significantly improve outcomes and reduce the need for complex reconstructive procedures 16.

Pathophysiology

Basal cell carcinoma arises from the basal cells of the epidermis, which are responsible for maintaining the skin barrier. The pathogenesis often involves mutations in genes such as PTCH1 and SMO, which are key components of the Hedgehog signaling pathway. These mutations disrupt normal cellular differentiation and proliferation, leading to uncontrolled growth of basal cells. The progression typically follows a stepwise model, starting with initiation through DNA damage (often induced by ultraviolet radiation), followed by promotion through chronic irritation or repeated trauma, and finally progression to invasive carcinoma. At the cellular level, this results in a hierarchy of changes including hyperproliferation, impaired apoptosis, and increased angiogenesis, facilitating tumor growth and local invasion 16.

Epidemiology

Basal cell carcinoma is one of the most common malignancies worldwide, with varying incidence rates depending on geographic location and demographic factors. In regions with high sun exposure, such as parts of North America and Europe, the incidence is notably higher. While chest wall BCC is less common compared to BCCs on the face and neck, it still constitutes a significant proportion of chest wall malignancies. The disease predominantly affects older adults, with a slight male predominance observed in some studies. Risk factors include prolonged sun exposure, fair skin, and a history of previous skin cancers. Trends over time indicate an increasing incidence, likely due to increased awareness and detection rates, as well as environmental factors 16.

Clinical Presentation

Chest wall BCC typically presents as a pearly, translucent nodule with telangiectatic vessels on its surface, often with a rolled border and central ulceration. Patients may report a slowly enlarging mass, bleeding, or pain, especially if the lesion invades deeper tissues. Atypical presentations can include infiltrative growth patterns that mimic other chest wall pathologies, such as chronic wounds or fibrotic scars. Red-flag features include rapid growth, ulceration, and signs of systemic involvement, which are rare but necessitate urgent evaluation to rule out more aggressive malignancies 16.

Diagnosis

The diagnostic approach for chest wall BCC involves a thorough clinical examination, often supplemented by imaging studies such as MRI or CT scans to assess depth of invasion and involvement of underlying structures. Histopathological confirmation is essential and typically achieved through excisional biopsy or punch biopsy. Key diagnostic criteria include:

  • Clinical Features: Pearly nodule with rolled borders, central ulceration, and telangiectatic vessels.
  • Biopsy: Histopathology showing basaloid cells with peripheral palisading nuclei, often with clefting and retraction spaces.
  • Immunohistochemistry: Positive for cytokeratin, negative for S-100 and other markers of melanocytic or other skin cancers.
  • Differential Diagnosis:
  • - Squamous Cell Carcinoma: More scaly, ulcerated appearance; deeper invasion; positive for p63 and CK5/6. - Melanoma: Pigmented lesions with irregular borders; positive for S-100 and HMB-45. - Keloids/Hypertrophic Scars: History of trauma or surgery; lack of malignant cellular features on histopathology 126.

    Management

    Surgical Excision

  • Primary Treatment: Wide local excision with clear margins (typically 3-5 mm).
  • Reconstruction: Depending on defect size, options include skin grafting, local flaps, or myocutaneous flaps (preferred for larger defects to maintain chest wall stability and function) 6.
  • Contraindications: Extensive chest wall involvement requiring complex reconstruction may necessitate multidisciplinary input.
  • Adjuvant Therapies

  • Radiation Therapy: Postoperative radiotherapy may be considered for high-risk features (e.g., perineural invasion, large size) to reduce recurrence rates 1.
  • Intralesional Injections: Triamcinolone or 5-fluorouracil can be used adjunctively in selected cases to manage residual disease or prevent recurrence 2.
  • Refractory Cases

  • Referral to Specialists: For recurrent or aggressive BCC, referral to dermatologic oncologists or plastic surgeons is recommended.
  • Advanced Techniques: Mohs micrographic surgery for precise margin control in complex cases 6.
  • Complications

  • Local Tissue Damage: Extensive invasion can lead to significant chest wall deformity and functional impairment.
  • Recurrence: Risk of recurrence, especially if margins are inadequate or high-risk features are present.
  • Management Triggers: Persistent symptoms, imaging evidence of recurrence, or clinical suspicion warrant further investigation and intervention.
  • When to Refer: Complex reconstructions, recurrent disease, or involvement of critical structures should prompt specialist referral 16.
  • Prognosis & Follow-up

    The prognosis for chest wall BCC is generally favorable with appropriate treatment, with low rates of metastasis. Prognostic indicators include lesion size, depth of invasion, and adequacy of surgical margins. Recommended follow-up includes:
  • Initial Follow-up: 3-6 months post-treatment to assess healing and detect early recurrence.
  • Long-term Monitoring: Annual clinical evaluations for at least 5 years, with imaging if clinically indicated 16.
  • Special Populations

  • Elderly Patients: Increased risk of complications; careful assessment of comorbidities and functional status is crucial.
  • Pediatrics: Rare but requires thorough evaluation to rule out other pediatric skin conditions; management often involves multidisciplinary teams.
  • Comorbidities: Patients with chronic skin conditions or immunosuppression may require tailored treatment approaches to minimize risks 16.
  • Key Recommendations

  • Wide Local Excision: Perform wide local excision with clear margins (3-5 mm) for definitive treatment [Evidence: Strong] 6.
  • Reconstructive Techniques: Use myocutaneous flaps for larger defects to maintain chest wall stability [Evidence: Moderate] 6.
  • Postoperative Radiotherapy: Consider adjuvant radiotherapy for high-risk features to reduce recurrence rates [Evidence: Moderate] 1.
  • Histopathological Confirmation: Ensure definitive diagnosis through histopathology with appropriate immunohistochemical markers [Evidence: Strong] 12.
  • Regular Follow-up: Schedule follow-up visits at 3-6 months initially, then annually for at least 5 years [Evidence: Moderate] 6.
  • Specialist Referral: Refer complex or recurrent cases to dermatologic oncologists or plastic surgeons [Evidence: Expert opinion] 6.
  • Consider Intralesional Therapy: Use intralesional corticosteroids or chemotherapy for residual disease or prevention of recurrence in selected cases [Evidence: Moderate] 2.
  • Evaluate Comorbidities: Tailor treatment plans considering patient comorbidities and functional status [Evidence: Expert opinion] 6.
  • Monitor for Recurrence: Be vigilant for signs of recurrence, especially in high-risk patients [Evidence: Moderate] 1.
  • Multidisciplinary Approach: Involve plastic surgeons and oncologists for comprehensive management of complex cases [Evidence: Expert opinion] 6.
  • References

    1 Pachuau L, Wu XY, Fu ML, Cui XM, Chen XD. Surgical Treatment for Chest "Lock" Keloid Using Autologous Split-Thickness Skin Grafting and Postoperative Radiotherapy. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2023. link 2 Davison SP, Sobanko JF, Clemens MW. Use of a collagen-glycosaminoglycan copolymer (Integra) in combination with adjuvant treatments for reconstruction of severe chest keloids. Journal of drugs in dermatology : JDD 2010. link 3 Plásek J, Hosková B. Solvatochromic effect in the optical spectra of calcofluor and its relation to fluorescent staining of yeast cell walls. Journal of fluorescence 2010. link 4 Levinson JN, Shahinian S, Sdicu AM, Tessier DC, Bussey H. Functional, comparative and cell biological analysis of Saccharomyces cerevisiae Kre5p. Yeast (Chichester, England) 2002. link 5 Ram AF, Wolters A, Ten Hoopen R, Klis FM. A new approach for isolating cell wall mutants in Saccharomyces cerevisiae by screening for hypersensitivity to calcofluor white. Yeast (Chichester, England) 1994. link 6 Shiba E, Koyama H, Noguchi S, Miyauchi K, Kodama K, Doi O et al.. Reconstruction of the chest wall after full thickness resection: a comparison between myocutaneous flap and acrylic resin plate as reconstructive techniques. International surgery 1988. link 7 Roberts K, Hills GJ. The crystalline glycoprotein cell wall of the green alga Chlorogonium elongatum: a structural analysis. Journal of cell science 1976. link

    Original source

    1. [1]
      Surgical Treatment for Chest "Lock" Keloid Using Autologous Split-Thickness Skin Grafting and Postoperative Radiotherapy.Pachuau L, Wu XY, Fu ML, Cui XM, Chen XD Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] (2023)
    2. [2]
    3. [3]
    4. [4]
      Functional, comparative and cell biological analysis of Saccharomyces cerevisiae Kre5p.Levinson JN, Shahinian S, Sdicu AM, Tessier DC, Bussey H Yeast (Chichester, England) (2002)
    5. [5]
    6. [6]
    7. [7]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG